Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 5/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.33 |
| ▸ | CFTR | P13569 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6506173 | 0.86 | SMN1; SMN2 (0.37) | MEN1ALDH1A1KMT2APOLB | |
| SCHEMBL6500555 | 0.86 | L3MBTL1 (0.35) | MEN1ALDH1A1KMT2APOLB | |
| SCHEMBL6498497 | 0.85 | TP53 (0.41) | MEN1ALDH1A1KMT2ACFTR | |
| SCHEMBL6388738 | 0.83 | POLB (0.43) | POLBHCRTR1 | |
| SCHEMBL6392731 | 0.81 | EPHX2 (0.33) | ALDH1A1 | |
| SCHEMBL6386637 | 0.81 | POLB (0.51) | ALDH1A1POLBTAAR1DRD2HCRTR1 | |
| SCHEMBL6501631 | 0.81 | POLB (0.51) | ALDH1A1POLBTAAR1DRD2HCRTR1 | |
| SCHEMBL6392200 | 0.81 | HPGD (0.43) | MEN1ALDH1A1KMT2APOLB | |
| SCHEMBL14440562 | 0.81 | NAMPT (0.39) | MEN1KMT2APOLB | |
| SCHEMBL6506781 | 0.80 | P2RX7 (0.39) | ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050239853-A1 | New compounds | BIOVITRUM AB (SE) | 2005-10-27 | — | — | US | claimed |
| US-20050239853-A1 | New compounds | BIOVITRUM AB (SE) | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239853-A1 | New compounds | HSD11B1, CYP11B1, HSD3B1 | MEN1 979/4885ALDH1A1 67/4885KMT2A 3213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.